| ErbB2/HER2-specific NK cells for targeted therapy of glioblastoma C Zhang, MC Burger, L Jennewein, S Genßler, K Schönfeld, P Zeiner, ... Journal of the National Cancer Institute 108 (5), djv375, 2016 | 357 | 2016 |
| Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor K Schönfeld, C Sahm, C Zhang, S Naundorf, C Brendel, M Odendahl, ... Molecular therapy 23 (2), 330-338, 2015 | 335 | 2015 |
| Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity C Zhang, P Oberoi, S Oelsner, A Waldmann, A Lindner, T Tonn, WS Wels Frontiers in immunology 8, 533, 2017 | 271 | 2017 |
| 3D model for CAR‐mediated cytotoxicity using patient‐derived colorectal cancer organoids TE Schnalzger, MHP de Groot, C Zhang, MH Mosa, BE Michels, J Röder, ... The EMBO journal 38 (12), e100928, 2019 | 243 | 2019 |
| Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor … S Genßler, MC Burger, C Zhang, S Oelsner, I Mildenberger, M Wagner, ... Oncoimmunology 5 (4), e1119354, 2016 | 177 | 2016 |
| Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma S Oelsner, ME Friede, C Zhang, J Wagner, S Badura, P Bader, E Ullrich, ... Cytotherapy 19 (2), 235-249, 2017 | 175 | 2017 |
| CAR-engineered NK cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy MC Burger, C Zhang, PN Harter, A Romanski, F Strassheimer, C Senft, ... Frontiers in immunology 10, 2683, 2019 | 171 | 2019 |
| A comparative study of different vector designs for the mammalian expression of recombinant IgG antibodies J Li, C Menzel, D Meier, C Zhang, S Dübel, T Jostock Journal of immunological methods 318 (1-2), 113-124, 2007 | 130 | 2007 |
| Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies P Nowakowska, A Romanski, N Miller, M Odendahl, H Bonig, C Zhang, ... Cancer Immunology, Immunotherapy 67, 25-38, 2018 | 90 | 2018 |
| “UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells N Mitwasi, A Feldmann, C Arndt, S Koristka, N Berndt, J Jureczek, ... Scientific reports 10 (1), 2141, 2020 | 78 | 2020 |
| Delivery of antibodies to the cytosol: debunking the myths ALJ Marschall, C Zhang, A Frenzel, T Schirrmann, M Hust, F Perez, ... MAbs 6 (4), 943-956, 2014 | 78 | 2014 |
| Analysis of IgG heavy chain to light chain ratio with mutant Encephalomyocarditis virus internal ribosome entry site J Li, C Zhang, T Jostock, S Dübel Protein Engineering, Design & Selection 20 (10), 491-496, 2007 | 69 | 2007 |
| Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia N Albinger, R Pfeifer, M Nitsche, S Mertlitz, J Campe, K Stein, ... Blood cancer journal 12 (4), 61, 2022 | 42 | 2022 |
| Suppression of p75 neurotrophin receptor surface expression with intrabodies influences Bcl-xL mRNA expression and neurite outgrowth in PC12 cells C Zhang, S Helmsing, M Zagrebelsky, T Schirrmann, ALJ Marschall, ... PloS one 7 (1), e30684, 2012 | 34 | 2012 |
| Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity C Zhang, J Röder, A Scherer, M Bodden, JP Serrahima, A Bhatti, ... Journal for immunotherapy of cancer 9 (10), 2021 | 33 | 2021 |
| Applying antibodies inside cells: principles and recent advances in neurobiology, virology and oncology C Zhang, RM Ötjengerdes, J Roewe, R Mejias, ALJ Marschall BioDrugs 34, 435-462, 2020 | 30 | 2020 |
| Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma MC Burger, MT Forster, A Romanski, F Straßheimer, J Macas, PS Zeiner, ... Neuro-oncology 25 (11), 2058-2071, 2023 | 22 | 2023 |
| P04. 05 The CAR2BRAIN study: a monocentric phase I trial with ErbB2-specific NK-92/5.28. z cells in recurrent glioblastoma MC Burger, I Mildenberger, C Zhang, K Ihrig, M Wagner, M Mittelbronn, ... Neuro-Oncology 18 (Suppl 4), iv24, 2016 | 11 | 2016 |
| Evaluating the delivery of proteins to the cytosol of mammalian cells ALJ Marschall, C Zhang, S Dübel Cancer Gene Networks, 201-208, 2017 | 8 | 2017 |
| Cd33 delineates two functionally distinct nk cell populations divergent in cytokine production and antibody-mediated cellular cytotoxicity M Hejazi, C Zhang, SB Bennstein, V Balz, SB Reusing, M Quadflieg, ... Frontiers in Immunology 12, 798087, 2022 | 7 | 2022 |
